Beauty Health Q4 2023 Earnings Call Transcript

Quartr
Provided by Quartr
March 12, 2024

There are 10 speakers on the call.

Operator

Good afternoon, everyone, and welcome to the Beauty Health Company's 4th Quarter and Full Year 2023 Conference Call. All participants will be in a listen only mode. Please also note this event is being recorded. And I'd like to turn the floor over to Roberto Aja, Investor Relations. Please go ahead.

Speaker 1

Thank you, operator, and good afternoon, everyone. Thank you for joining us today to discuss the Beauty Health Company's Q4 and full year 2023 financial results, which were released earlier this afternoon and can be found on our website at beautyhealth.com. Joining us on the call today are Beauty Health's Chief Executive Officer, Marla Beck along with Chief Financial Officer, Mike Monaghan. Before we begin, I would like to remind you of the company's Safe Harbor language. Management may make forward looking statements, including guidance and underlying assumptions.

Speaker 1

Forward looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. Listeners are cautioned not to place undue reliance on any forward looking statements. For further discussion of risks related to our business, please see the company's filings with the SEC. This call will present non GAAP financial measures. Reconciliation of these non GAAP financial measures to the most comparable GAAP measures are in the earnings press release furnished to the SEC and available on our website.

Speaker 1

Following management's prepared remarks, we will open the call for a question and answer session. With that, I would now like to turn the call over to Beauty Health's CEO, Marla Beck. Please go ahead, Marla.

Speaker 2

Thank you, Norberto, and thank you, everyone, for joining us on the call today. I want to start by thanking our Board of Directors for their trust and support as I formally take on the role of CEO of Beauty Health. I'm excited about the opportunity and I'm confident about the future of the company. I joined Beauty Health's Board of Directors in 2022 because I saw a much loved brand in an underpenetrated market, the space where beauty meets aesthetics. I built my career in this space and bring significant experience in sales, operations and new product development to the role.

Speaker 2

I founded Blue Mercury in 1999 as a specialty beauty retailer, featuring a selection of curated products alongside in store aesthetic treatments. It is a common format today, but it was novel when we started. We grew Blue Mercury to nearly 200 stores with 2 private label skincare brands, a healthy e commerce business and strong loyalty penetration before a strategic sale to Macy's in 2015. While my passion for the sector and knowledge of products and formulations success. I can see clearly how to put these elements in play for beauty health.

Speaker 2

Over the last few months, I've spent my time meeting with our providers, getting to know our sales team, testing our products and gaining a deep understanding of our operational capabilities. During this time, I've come to understand the unique proposition of our brand and products, the engagement of our providers and consumers and the wide open opportunity ahead. I also understand the careful work that will be required for Beauty Health to meet our ambitions and growth potential. The Board, the executive management team and I are fully aligned to deliver against 3 key priorities over the near term. We will drive sales excellence, operational excellence and financial discipline.

Speaker 2

Our first priority is sales excellence. The treatment room is the center of our business and providers and our sales teams are the face of the brand in many ways. I learned early in my career the importance of staying close to the customer from helping aestheticians turn rooms at our Blue Mercury store in Georgetown because they were so busy with treatments or helping to sell on the retail floor during the busiest holiday periods. And so that's how I asked the Beauty Health Executive Committee to start the year in the treatment rooms with providers. We fanned out across the globe with our frontline sales teams to meet more than 50 providers in the past 50 days.

Speaker 2

The feedback was insightful and grounding. I will share just a few themes we heard. First, providers know and appreciate that we put them front and center. 2nd, they despite the issues with the early versions of Syndeo, Syndeo 3.0 is a better platform. 3rd, they recognize and value the unmatched efficacy of our treatment and the power of the HydraFacial brand to bring consumers through their doors.

Speaker 2

Importantly, the challenges providers experience with Syndea 1.02.0 have not impacted the consumer experience. We hear repeatedly from providers that HydraFacial is a brand clients ask for by name. We see this in the steady consumables revenue growth in the Americas and in indicator metrics like Google search trends, which show an uptick in interest globally of 21% in 2023 versus 2022. We are fortunate to have an experienced and tenured sales team who have developed deep relationships with our providers. It is incredible to see their connections and willingness to go above and beyond.

Speaker 2

Our training and education team is best in class, supporting providers in their craft and helping them to build profitable revenue streams for their businesses. And our marketing team is thoughtfully building on a brand loved by providers and consumers alike, an incredibly unique and valuable element of our business in an industry that is largely driven by brand less treatment modalities. We will continue to hold ourselves to high performance standards expected from HydraFacial and always put our providers and consumers first. Our second priority is operational excellence. We will tighten our operations, prioritizing our focus on our strongest growth opportunities and establishing accountability across our supply chain.

Speaker 2

We are undertaking a total review of our full manufacturing and operations footprint and we'll provide an update on our findings later this year. Much of the recent focus has been on executing the Zendaya program announced last quarter, ensuring all Zendaya's globally meet our latest 3.0 standard and that we protect our valuable provider relationships. The early feedback regarding Syndeos 3.0 is positive. While we still hear some concerns regarding the 3.0 system, the level is consistent with industry standards and we are addressing issues that come up quickly. We will continue to prioritize operational excellence and always with the provider in mind.

Speaker 2

Finally, our 3rd near term priority is financial discipline. We will be cost conscious in everything we do, balancing our cost structure with revenue and opportunity. We will bring increased transparency and consistency to our financial results through improved forecasting. Mike and I are aligned on this point, which you can see clearly in our 4th quarter results with revenue and adjusted EBITDA in line with guidance. Mike will share these details shortly.

Speaker 2

These 3 near term priorities sales excellence, operational excellence and financial discipline are foundational and necessary to operate from a position of strength and leverage the opportunities in front of us. Since joining the Board in June of 2022, a few things have become very clear to me about the significant growth runway, which we will begin to which we will see begin to take shape in the second half of 2024 and beyond. We see an attractive opportunity around consumables to drive further penetration. This is a focus of mine. We will have more to report on our plans and progress later this year.

Speaker 2

We also see a clear opportunity to grow our device installed base by leveraging the specific value we bring to each provider channel, whether in medical practices, med spas, hospitality locations, retail or with single room Estes. We are in the early innings of addressing the opportunity across the vast majority of markets where we operate. Increasing penetration in existing markets to achieve scale is something we are confident we can execute on. I want to emphasize, however, that our focus for now is squarely on implementing a transformation of the company. This entails driving sales excellence globally, keeping our provider at the center of everything we do, Investing the necessary resources to drive operational excellence and operating with added financial discipline strategic and optimal deployment of our resources.

Speaker 2

As we continue to build and rebuild the foundation of Beauty Health, I'm confident we will soon be able to leverage the opportunities ahead of us to deliver long term value to our employees, partners and shareholders. We have a magnificent brand, terrific products, strong partner and customer relationships, healthy underlying market trends and ample call over to Mike to share details of our Q4 and full year 'twenty three performance.

Speaker 3

Thank you, Marla. I'll start by commenting on our full year 2020 3 financial results and Q4 performance as well as provide details behind our financial guidance for 2024. Revenue for the full year 2023 came in at $398,000,000 representing 8.8% year over year growth. Revenue was driven by steady consumables growth in the Americas and strong international performance with nearly 43% of sales coming from APAC and EMEA. Global equipment revenue was relatively flat for the year, up 0.2% primarily driven by lower provider adoption in the Americas due to Zendeo challenges.

Speaker 3

Total active machines in the field increased 24 percent to 31,446 units over the course of the year as we grew our provider base. Consumable sales increased 19.9 percent year over year to $191,400,000 reflecting continued and growing consumer interest in the HydraFacial treatments. Consumables represent 48.1 percent of total revenue. Gross margin for the full year of 2023 was 39% versus 68% in the prior year period on a GAAP basis and 62.8% versus 72.6%, respectively, when we adjust for non cash expenses and selected add backs. The primary drivers of the decline on a GAAP basis were the Syndeo 3.0 program and higher charges related to other discontinued excess and obsolete products.

Speaker 3

Adjusted EBITDA came in at $24,300,000 or 6.1 percent of revenue versus $46,100,000 or 12.6 percent of revenue in the prior year, representing a 47.2% decline year over year. Moving to Q4 performance. Q4 2023 revenue and adjusted EBITDA results were at or above the guidance we gave on our Q3 earnings call. Revenue for the quarter declined by 1.3% year over year to $96,800,000 We saw Americas revenue decline 8 point 5% year over year, primarily driven by soft device sales due to customer caution around Zendayo and higher interest rates. As Marla mentioned, we are beginning to see Syndeo concerns subside and expect capital momentum will pick up.

Speaker 3

For the quarter, APAC revenue grew 17.3% year over year to 18,700,000 dollars China accounted for $14,200,000 of the region's contribution, showing 71.8% year over year growth. The performance was driven by strong delivery system placements reflecting our success in penetrating the market and the significant potential to grow our nascent presence as well as a partial COVID shutdown during a portion of Q4 of 2022. EMEA Q4 revenue grew 8.4% year over year to $18,800,000 with strength coming from consumables. Moving on to revenue by product type. For the quarter, consumable sales of $52,200,000 eclipsed equipment sales accounting for 53.9 percent of revenue and a 10% year over year increase.

Speaker 3

On the systems side, we saw a 12% decline year over year in revenue to $44,600,000 driven by lower system sales in both the Americas and EMEA, partially offset by 66% revenue growth in APAC. During the quarter, we sold 1551 systems at an average selling price of $28,783 up year over year primarily due to a favorable mix shift towards direct markets in APAC and EMEA and a higher percentage of Syndeo systems sold. Of the 15 51 systems, 341 were trade ups. We delivered consolidated GAAP gross profit of $45,700,000 resulting in a GAAP gross margin of 47.2%. During the 4th quarter, we incurred inventory related charges of $8,700,000 We did not add back these charges to our adjusted gross margin as our intention is to minimize our add backs going forward.

Speaker 3

In 2024, we are focused on improving our demand planning process and overall inventory management. Adjusting for non cash charges such as depreciation, amortization and stock based compensation and incremental Syndeo program charges, adjusted gross profit was $52,800,000 for a 54.6 percent adjusted gross margin. Selling and marketing expense was $32,000,000 down approximately R and D expense was $3,000,000 up $1,600,000 year over year. G and A expense was $29,000,000 up $500,000 year over year, primarily driven by higher severance, bad debt reserve, depreciation and amortization and software expenses. Altogether, this resulted in a net loss of $9,400,000 Normalizing for non cash items and certain discrete charges, adjusted EBITDA was $3,400,000 primarily due to gross margin pressure.

Speaker 3

This compares to a net income of $6,500,000 and adjusted EBITDA of 17.6 $1,000,000 in Q4 2022. Moving to the balance sheet. We ended the quarter with approximately $523,000,000 of cash. As of December 31, we had approximately $70,000,000 remaining on our existing share repurchase authorization. In the Q4, we repurchased 9,900,000 shares at an average price of $2.80 per share.

Speaker 3

In January of 2024, we deployed $57,800,000 of cash to purchase $75,000,000 of our debt. We feel comfortable with our current liquidity position and together with our Board, we'll continue to evaluate capital allocation, including debt management. We will provide investors with any updates on our capital allocation on future quarterly calls. Our inventory stood at approximately $91,300,000 at the end of December, a decrease compared to $109,700,000 in December 2022. We increased our inventory during the Q4 as we began to build and deliver replacement Zendaya 3.0 units to our provider base.

Speaker 3

Additionally, at the end of the Q4, we had approximately 1300 trade up elites on our balance sheet at the estimated resale price less our cost to resell. We are planning to sell through this inventory over the next 2 years and have factored in roughly half of the existing inventory to be sold during 2024. Starting in 2024, we are no longer taking back older equipment to resell and instead will offer our providers other incentives to upgrade. Including our sales of new 3.0 machines, we ended our fiscal year 2023 with roughly 9,500 Zendeso systems sold globally and approximately 3,000 systems are left to be upgraded to the 3.0 model. We continue to make progress on this initiative and expect to be completed with the program during the first half of twenty twenty four.

Speaker 3

Our December year end accrual for the Zendaya replacement program $21,000,000 down from approximately $32,000,000 at the end of September 2023. We have a year end warranty accrual of approximately $6,000,000 as of December 2023 to cover our total global systems inclusive of extended Zendaya warranties we issued to support our providers during 2023. Next, I want to update you on our business transformation program that we announced in September. As a reminder, our initial target for the program was $20,000,000 in annualized Phase 1 cost savings beginning in March 2024, Phase 1 cost savings beginning in March 2024 with an incremental $15,000,000 of annualized Phase 2 cost savings beginning in June 2024. Phase 1 gross cost savings of approximately $15,000,000 were realized in Q4 of 2023 by reducing our workforce by roughly 10%.

Speaker 3

Planned Phase 2 cost savings were expected to be driven by optimizing manufacturing operations and reducing operating spend. In 2024, we made decision to reallocate most of these initial and expected cost savings towards necessary investments in systems, processes and training to implement stronger management of and controls around our supply chain and inventory. We recently identified a material control weakness in our inventory controls and are making the necessary investments to address this issue immediately. We expect many of these investments to be short term in nature and to position us to realize meaningful cost savings in future years. Additionally, we will continue to work through other areas where we believe we can drive efficiencies and reduce our overall spend.

Speaker 3

We believe these actions will result in long term net savings. I would like to take a moment to discuss the revenue cadence and seasonality of our business. Revenue is typically highest in the second and fourth quarters of the year. This is due to 2 factors. 1st, capital purchases historically are largest in the 4th quarter as our provider base often has clear visibility into their annual capital spend allowance by that point in the year.

Speaker 3

2nd, the second and fourth quarters will often have the highest consumer demand for HydraFacial treatments in the spring and then again in the fall. This is consistent with aesthetics and beauty trends and bolstered by our twice annual consumables promotion periods in May and Black Friday in November. Given the size of our growing business, these two drivers have an impact on the cadence of our revenue. At the same time as the Q1 of each year is a traditionally slower revenue period for the business, we see a large share of sales and marketing spend in the form of the major trade shows and events during Q1. These shows and events are important lead generators and training for the year, but the spend versus revenue puts pressure on the quarter's EBITDA.

Speaker 3

It is important to remember that our business is a razor razorblade model with roughly even revenue split between capital and consumables today. Our consumables segment represents a growing predictable and high margin recurring revenue stream. Longer term, as with any razor razorblade model, we can expect consumables will become a larger portion of our revenue mix and the seasonality of the business will flatten with revenue becoming more evenly distributed over the year. Keeping in mind the seasonality of our business, I'll move on to guidance for 2020 4. In the Q1, we expect net sales to be $77,000,000 to $83,000,000 and an adjusted EBITDA loss of $6,000,000 to $9,000,000 We expect revenue to be down year over year in the Q1 of 2024, primarily driven by soft equipment sales in the Americas as we regain provider confidence in Zendaya 3.0 with a return to growth in the back half of the year.

Speaker 3

Additionally, we expect to face a challenging year over year comparison for system sales in APAC and EMEA in the first half of twenty twenty four with our international SYNDEO launch in the 2023 comparable period. Adjusted gross margin is expected to be lower in the first half of twenty twenty four compared to the first half of twenty twenty three as we make investments in our controls, processes and procedures and overall supply chain. For the full year, we expect to improve slightly year over year with supply chain efficiencies later in 2024, partially offset by pricing pressure as we transition away from our trade up program and support our sales efforts with lower average selling prices for our systems. Additionally, in the first half of the year, we will plan to continue to invest in sales and marketing to generate leads as is typical in our industry. These expenses are expected to lessen in the second half of the year.

Speaker 3

Resulting from the above assumptions for the full year 2024, we are projecting revenue growth to be flat to up single digits year over year, but expect to deliver adjusted EBITDA of $40,000,000 or greater as we are prioritizing growing profitability alongside foundational priorities Marla discussed. As we stated on our previous earnings call, our goal is to execute with a simpler structure while meeting the high expectations of our providers, consumers, partners and shareholders. Our action plan is clear. We'll increase our footprint through new capital equipment sales. We plan to increase consumable sales per system, stabilize the business and complete our Syndeo 3.0 replacement program and drive profitability.

Speaker 3

I'll now turn the call to the operator for Q and A.

Operator

And our first question today comes from Olivia Tong from Raymond James. Please go ahead with your question.

Speaker 4

Great. Thanks. Good afternoon. I wanted to build on some of the comments that you made about sales growth and cadence as it would suggest sort of a low to mid single digit growth in Q2 to Q4. So can you talk about the building blocks to get you there?

Speaker 4

And then secondly, you mentioned in your prepared comments the strategic pullback in marketing spend. You also said that the customer didn't really see any issue and that was a really important point. So could you talk about the decision to sort of curtail marketing spend? Because I would imagine that given the disruption behind the scenes, if the customer didn't see it, you would want to maintain that marketing spend to make sure that they aren't aware of any disruption behind the scenes? Thanks so much.

Speaker 3

Hi, this is Mike. I'll address the first both questions I can address. So the first part was around the overall guidance. So let me talk a little bit about what's driving that. So there's a couple anticipated drivers of pressure in the first half of the year that I can talk through.

Speaker 3

And then we're expecting to return to growth on the top line in the back half of the year. The first driver is system sales are projected to grow in Americas as we complete our Syndeo replacement program. We're already starting to see increased interest as we move past the challenges of Syndeo launch. The second piece I mentioned in the prepared remarks is in the international markets, we launched Syndeo in the first half of last year. So as we look to that comp, it gets a little bit easier in the back half of the year as we move past that.

Speaker 3

The 3rd piece is really around consumable sales per system. As a result of some of the challenges with Zendaya, we saw pressure in the back half of twenty twenty three. We're actively working with our providers to support them and we expect to increase those consumable sales per system and as we enter into the back half. The second part of your question was around marketing spend. We traditionally spend more marketing upfront, as we talked about related to provider, trade shows, conferences, they tend to be front loaded in Q1 specifically and a little bit in Q2 during the year.

Speaker 3

And a significant portion of that expense runs through our sales and marketing. So you start to see that typically run down in the back half of the year. One thing I would like to highlight is we still have allocated costs in the back half of the year. So it's not like we're turning that spend off. We're still planning on spending and supporting our providers.

Speaker 3

It's just to a lesser degree in the second half than it is in the first half.

Operator

Our next question comes from Oliver Chen. Please go ahead with your question.

Speaker 5

Hi. Thanks, Marlon. Mike, on some of our research, we're still seeing some issues with Zendaya 3.0, but it sounded like it's in really good shape. Just any color on what gives you confidence and risk factors there? And as you mentioned, supply chain and controls both have opportunity.

Speaker 5

How would you contrast what needs to be done with respect to controls relative to supply chain? And finally, capital allocation priorities, you mentioned them on the call. Just would love a framework for how you're thinking about capital allocation priorities going forward. Thank you.

Speaker 2

I'll start and then Mike can pick up the rest. But so I would say with Zendaya 3.0, we're encouraged by what we're seeing. It's better than 1.02.0. But we still have work to do around getting quality, to the level which we think is what we want. And so there's still work, but we've made a ton of progress.

Speaker 2

So I think that's a start. I'm going to let Mike take the supply chain and capital allocation pieces of your question and add anything to sort of what I said if you would like Mike?

Speaker 3

Sure. On overall operations, we're making investments in information management, so systems, our overall process and procedures, and to make sure we're looking at the right things and managing our overall inventory controls. And that's some of the things I talked about, why we assess ourselves with the material weakness. The material weakness is really around making sure we have the right people with the right experience and the right processes in place to effectively manage inventory and the related obligations. The second part of your question around capital allocation, that's something right now where we're spending time with the Board.

Speaker 3

We have a capital allocation committee on the Board. We meet regularly, and are discussing. I don't really have anything more than what we've actually done to address right now. But as soon as we do make any additional changes or we'll be sure to update investors then.

Operator

Our next question comes from Alan Gong from JPMorgan. Please go ahead with your question.

Speaker 6

Thanks for the question and congratulations, Marla, for the position. Just to start off on kind of like a higher level, I had imagined that your previous targets presented at the 2022 Analyst Day are no longer in effect. But just when we think about the outlook for the company, once we move past this continued transition period in 2024, how should we think about your prioritization between driving continued top line growth and EBITDA as it seems like in 2024, you're kind of rebasing EBITDA and growth that might be suffering a little bit as a result. So how should we think about that going forward?

Speaker 3

We're not in a position to give long term guidance today, but what we can talk about is our focus is we really believe that there is growth in this business, a lot of room to grow. We think that we can grow profitably, and that's a specific focus of what we're working through now. The levers that we expect to improve upon over the long term is we think there's opportunity in gross margin. And then as you look in OpEx, we talked about some of our initial OpEx savings that we're reinvesting back into the business over the short term. But we do believe there's long term scale in our operating expenses that we can realize.

Speaker 3

We're just taking a little bit of time this year to make sure we can implement them in an effective way.

Operator

Our next question comes from Susan Anderson from Canaccord Genuity. Please go ahead with

Speaker 6

Alec Legg on for Susan. Just wondering if you could talk about the trends as usage frequency by machine and then some of the add ons? And then longer term, where do you think that add on business can go?

Speaker 3

Sure. I can talk a little bit about the consumables growth and then I can move on. So overall, the increase in consumable growth was driven by the Americas and EMEA, and it was offset in APAC, as you mentioned. APAC consumables revenue is down 30% year over year in Q4. That was primarily driven by softness in the distributor channel, which we're in the process of there's often some timing relating to the distributor channel, but we're in the process of addressing and researching right now.

Speaker 3

It's important to note China consumable sales, which are mostly sold directly, were down a couple of percentage points year over year. So as we continue to grow our systems base in APAC, we believe there is a large opportunity to drive consumable revenue in the future. Some of the things that we're investing behind are additional boosters and products that are specifically designed for the APAC market that we can talk about kind of later this year as we plan to launch them. The second part of your question, I think, was around overall consumables usage. We're still working through the specific metrics that we want to communicate externally.

Speaker 3

But one of the key metrics that we focus in on internally is consumable sales per system. And this is something that we're tracking and expect to drive up over in the future. When you look at Q4 and last year, that was down year over year, primarily because of the APAC market and we're going to we're focused on addressing it based on the things I just mentioned.

Operator

Our next question comes from Jon Block from Stifel. Please go ahead with your question.

Speaker 7

Thanks guys. Good afternoon. Maybe I'll just try to jam 2 in a 1. Just first, your worldwide consoles, I believe they were down roughly 35% year over year. Maybe if you could just talk about the overall capital environment and how you think you guys did from a market share perspective relative to that down 35%.

Speaker 7

And then just you talked about the EBITDA in the back end weighted nature, but just how do we think about the free cash flow? I mean, obviously, Mike, we've seen in past years with you guys a big delta between EBITDA and free cash flow. Asking about that because we're going to start coming up in the converts in 2026 before you know it. It seems like you feel pretty good considering you still proceeded with the share repo, but any color would be helpful. Thanks guys.

Speaker 3

So I can take the first I'll take the first couple and then Marla if you have other things to add. I think if I understood John the first part of the question it was around kind of our overall equipment revenue and sales and how that's relative to the market. I don't have specific data on how we compare to the market. I think for us, some of the challenges we saw in equipment sales really had to do with some of the issues we had internally with Zendaya overall. And so as I said, we're starting as we launched 3.0 and have really reached out to our providers, we're starting to our expectation is that over the next couple of quarters, we're going to see that kind of pick back up.

Speaker 3

Your question around EBITDA and free cash flow, we talked about in the guidance that we would do at least $40,000,000 or above of adjusted EBITDA. Our intention is not to have significant cash based add backs to get to adjusted EBITDA. And so our CapEx projections for the year will be roughly $15,000,000 to $20,000,000 So overall, our expectation in the guidance that we gave is that we would generate flat to some adjusted free cash flow or some free cash flow from those numbers. In terms of the overall capital structure, as we talked about, we're very much aware of the debt maturities on the convert, which is in the later in 2026, in Q4 of 2026. And so that's something that we are feel like we have time and are in a good position where we sit today.

Operator

Our next question comes from Corrine Wolfmeyer from Piper Sandler. Please go ahead with your question.

Speaker 8

Hey, good afternoon team. Thanks for taking the question. So I think you alluded to and there was a prior question on some of the other issues Syndeo 3.0 has been seen. I mean, we've all done our work. So I just want to understand like what exactly are you seeing that are ongoing things?

Speaker 8

And what are you doing to address them? And then I think in the prepared remarks, you also said you're getting rid of the trade up program, but maybe offering some incentives to upgrade to Zendaya. Sounds like that might be some pricing actions. So what exactly are you doing in lieu of the trade ups? And what should we be expecting with that program going forward?

Speaker 8

Thanks.

Speaker 2

I mean, I'll work on that. I mean, the Syndeyance 3.0 issues aren't the same issues we've had in the past, right? We have some noise issues, quality issues we need to continually focus on to improve, but not like the issues we had with 1.0s and 2.0s. This comes with sort of a full operational review on every single thing we do around fulfillment and supply chain, which is an absolute priority for us. Mike, do you want to add anything on that?

Speaker 3

No, I can adjust the trade offs there if you want to.

Speaker 2

Yes. I mean, with trade offs, I mean, we're just restructuring sort of how we do them, which is offering incentives to actually trade into the Zendaya without taking the existing device back. So what happens really is that it's an added device for many of our providers.

Operator

And our final question today comes from Ashley Helgans from Jefferies. Please go ahead with your question.

Speaker 9

Hey, thanks for taking our question. I guess just to kind of ask in a different way. I think you mentioned some of the providers have given some concerns around the Zendaya 3.0. Just any color you can give us on like the concerns you're hearing from the providers will be super helpful. And then you've had a significant growth in China.

Speaker 9

Any kind of color on the market there like where you are like what inning you're in, in the China market? How much runway do you still have there would be super helpful as well? Thanks.

Speaker 3

I can take in if Marla has anything to add. So let me take your there's not really much more that I have to add than what Marla talked about, about what seeing with Zendaya. I'll just kind of repeat. These are more quality control issues that we're addressing. And when you look at the overall guidance and when we talk about reinvesting back into the business in the near term, it's really around those types of things to ensure that when a product comes off the production line that we are doing the right things in terms of inspecting it, making sure it gets to our ultimate provider in good shape.

Speaker 3

Some of the issues we've had recently are around if some of the products have moved during shipping, so it's creating noise. Some of the there has been some aesthetic like problems with scratches or issues with the machine itself. So we're working to kind of make sure we address and make sure that our providers get a quality product upon receipt. The second part of your question was around

Speaker 2

China.

Speaker 3

Oh, China. Yes, we think we're early in China as we've talked about. We think there's a lot of growth there. We're still working to introduce new boosters, new products on the consumables. And as you can see based on the results, we're still growing quite nicely in terms of deploying equipment there and we expect that to kind of continue and factor that into our guidance.

Operator

And ladies and gentlemen, with that, we'll conclude today's question and answer session. I'd like to turn the floor back over to Ms. Beck for any closing remarks.

Speaker 2

Thank you all for joining us today. We're excited. This is the beginning of our time with you and look forward to really doubling down and getting to where we need to be. Thank you.

Operator

And ladies and gentlemen, with that, we'll conclude today's conference call and presentation. We thank you for joining. You may now disconnect your lines.

Powered by Quartr
Earnings Conference Call
Beauty Health Q4 2023
00:00 / 00:00